Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) dropped 1.3% on Wednesday . The stock traded as low as $55.30 and last traded at $57.78. Approximately 3,867,270 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 5,141,932 shares. The stock had previously closed at $58.57.
Analysts Set New Price Targets
A number of analysts recently issued reports on the company. Guggenheim reissued a "buy" rating on shares of Tempus AI in a report on Tuesday, February 25th. Piper Sandler lowered their price target on shares of Tempus AI from $70.00 to $55.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Morgan Stanley boosted their price objective on shares of Tempus AI from $50.00 to $60.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. Wolfe Research lowered shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. Finally, Bank of America raised their price target on shares of Tempus AI from $54.00 to $60.00 and gave the company a "neutral" rating in a report on Monday, March 3rd. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $61.18.
Check Out Our Latest Research Report on TEM
Tempus AI Price Performance
The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The business has a fifty day moving average price of $58.38 and a 200-day moving average price of $51.48.
Insiders Place Their Bets
In other Tempus AI news, COO Ryan Fukushima sold 20,000 shares of the company's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $39.61, for a total transaction of $792,200.00. Following the completion of the sale, the chief operating officer now directly owns 982,442 shares in the company, valued at $38,914,527.62. This represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Bradley A. Keywell sold 170,720 shares of the firm's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $35.45, for a total value of $6,052,024.00. Following the transaction, the insider now directly owns 15,993,729 shares in the company, valued at $566,977,693.05. This trade represents a 1.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,598,969 shares of company stock valued at $317,194,162 over the last quarter.
Institutional Trading of Tempus AI
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Operose Advisors LLC purchased a new position in shares of Tempus AI in the fourth quarter worth $25,000. Farther Finance Advisors LLC bought a new stake in Tempus AI in the 4th quarter worth $34,000. Prestige Wealth Management Group LLC grew its holdings in Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after acquiring an additional 965 shares during the last quarter. NewEdge Advisors LLC purchased a new position in shares of Tempus AI in the fourth quarter valued at about $49,000. Finally, First Horizon Advisors Inc. raised its stake in shares of Tempus AI by 207.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock valued at $55,000 after acquiring an additional 1,108 shares during the last quarter. Institutional investors own 24.22% of the company's stock.
Tempus AI Company Profile
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Further Reading
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.